SAN

85.97

-0.43%↓

MRK1

110.15

-0.81%↓

ARGX

798

-1.14%↓

PHIA

23.19

-0.98%↓

ONC.US

349.43

-0.74%↓

SAN

85.97

-0.43%↓

MRK1

110.15

-0.81%↓

ARGX

798

-1.14%↓

PHIA

23.19

-0.98%↓

ONC.US

349.43

-0.74%↓

SAN

85.97

-0.43%↓

MRK1

110.15

-0.81%↓

ARGX

798

-1.14%↓

PHIA

23.19

-0.98%↓

ONC.US

349.43

-0.74%↓

SAN

85.97

-0.43%↓

MRK1

110.15

-0.81%↓

ARGX

798

-1.14%↓

PHIA

23.19

-0.98%↓

ONC.US

349.43

-0.74%↓

SAN

85.97

-0.43%↓

MRK1

110.15

-0.81%↓

ARGX

798

-1.14%↓

PHIA

23.19

-0.98%↓

ONC.US

349.43

-0.74%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Avatud

18.2 -1.83

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.38

Max

18.48

Põhinäitajad
By Trading Economics
Sissetulek	-46M
Müük	-21M
Kasumimarginaal	221.361
Töötajad	103
EBITDA	-44M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+26.1% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. nov 2025

Turustatistika
By TradingEconomics
Turukapital	943M
Eelmine avamishind	20.03
Eelmine sulgemishind	18.2

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. nov 2025, 23:07 UTC

Market Talk

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20. nov 2025, 22:22 UTC

Market Talk

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20. nov 2025, 22:08 UTC

Market Talk

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20. nov 2025, 21:57 UTC

Tulu

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

20. nov 2025, 21:31 UTC

Tulu

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20. nov 2025, 21:23 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. nov 2025, 21:07 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q Rev $156.9M >BULL

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q EPS 7c >BULL

20. nov 2025, 21:05 UTC

Tulu

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20. nov 2025, 21:04 UTC

Tulu

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Consumer Rev $894M

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Guidance

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Global Business Solutions Rev $3B

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

26.1% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 26.1%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.